A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing

Vaccine

Volumn 31, Issue 15, 2013, Pages 1999-2007

  Saade, Fadi ^a   Honda Okubo, Yoshikazu ^a   Trec, Samay ^a   Petrovsky, Nikolai ^a,b  

^a VAXINE PTY LTD   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Adjuvant; Advax ; Alum, Therapeutic; Hepatitis B; Inulin; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CYTOKINE; DELTA INULIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INULIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMETRIC BEAD ARRAY; FEMALE; GUINEA PIG; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REACTOGENICITY; TH1 CELL; TH17 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; FEMALE; GUINEA PIGS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INULIN; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, HELPER-INDUCER; VACCINATION;

EID: 84875257910     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.077     Document Type: Article

References (40)

1. Andre F.E. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989, 87(September (3A)):14S-20S.
2. Keating G.M., Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003, 63(10):1021-1051.
3. Milich D.R., Thornton G.B., Neurath A.R., Kent S.B., Michel M.L., Tiollais P., et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 1985, 228(June (4704)):1195-1199.
4. Milich D.R., McLachlan A., Chisari F.V., Kent S.B., Thorton G.B. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg. J Immunol 1986, 137(July (1)):315-322.
5. Shapira M.Y., Zeira E., Adler R., Shouval D. Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. J Hepatol 2001, 34(January (1)):123-127.
6. Zuckerman J.N., Zuckerman A.J. Recombinant hepatitis B triple antigen vaccine: Hepacare. Expert Rev Vaccines 2002, 1(August (2)):141-144.
7. Rendi-Wagner P., Kundi M., Stemberger H., Wiedermann G., Holzmann H., Hofer M., et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001, 19(February (15-16)):2055-2060.
8. Mahboubi A., Fazeli M.R., Dinarvand R., Samadi N., Sharifzadeh M., Ilka H., et al. Comparison of the adjuvanticity of aluminum salts and their combination in hepatitis B recombinant protein vaccine in assessed mice. Iran J Immunol 2008, 5(September (3)):163-170.
9. Gilbert C.L., Klopfer S.O., Martin J.C., Schodel F.P., Bhuyan P.K. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults≥50 years. Hum Vaccines 2011, 7(December (12)):1336-1342.
10. Tohme R.A., Awosika-Olumo D., Nielsen C., Khuwaja S., Scott J., Xing J., et al. Evaluation of hepatitis B vaccine immunogenicity among older adults during an outbreak response in assisted living facilities. Vaccine 2011, 29(November (50)):9316-9320.
11. Fabrizi F., Dixit V., Messa P., Martin P. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials. Vaccine 2012, 30(March (13)):2295-2300.
12. Levie K., Gjorup I., Skinhoj P., Stoffel M. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. Scand J Infect Dis 2002, 34(8):610-614.
13. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Adhami M.A., Krieg A.M., et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004, 24(November (6)):693-701.
14. Halperin S.A., Ward B., Cooper C., Predy G., Diaz-Mitoma F., Dionne M., et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine 2012, 30(March (15)):2556-2563.
15. Nevens F., Zuckerman J.N., Burroughs A.K., Jung M.C., Bayas J.M., Kallinowski B., et al. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients. Liver Transplant 2006, 12(October (10)):1489-1495.
16. Petrovsky N. Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev Vaccines 2008, 7(February (1)):7-10.
17. Halperin S.A., Dobson S., McNeil S., Langley J.M., Smith B., McCall-Sani R., et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006, 24(January (1)):20-26.
18. Lobigs M., Pavy M., Hall R.A., Lobigs P., Cooper P., Komiya T., et al. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol 2010, 91(June (Pt 6)):1407-1417.
19. Cristillo A.D., Ferrari M.G., Hudacik L., Lewis B., Galmin L., Bowen B., et al. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol 2011, 92(January (Pt 1)):128-140.
20. Honda-Okubo Y., Saade F., Petrovsky N. Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine 2012, 30(August (36)):5373-5381.
21. Layton R.C., Petrovsky N., Gigliotti A.P., Pollock Z., Knight J., Donart N., et al. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine 2011, 29(August (37)):6242-6251.
22. Eckersley A.M., Petrovsky N., Kinne J., Wernery R., Wernery U. Improving the dromedary antibody response: the hunt for the ideal camel adjuvant. J Camel Pract Res 2011, 18(1):35-46.
23. Gordon D.L., Sajkov D., Woodman R.J., Honda-Okubo Y., Cox M.M., Heinzel S., et al. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant. Vaccine 2012, 30(August (36)):5407-5416.
24. Diminsky D., Schirmbeck R., Reimann J., Barenholz Y. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine 1997, 15(April-May (6-7)):637-647.
25. Hedman K., Rousseau S.A. Measurement of avidity of specific IgG for verification of recent primary rubella. J Med Virol 1989, 27(April (4)):288-292.
26. Yuasa T., Shimojo H. Potency test of hepatitis B vaccines by the parallel line assay method in mice. Jpn J Med Sci Biol 1985, 38(February (1)):9-18.
27. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136(April (7)):2348-2357.
28. Locksley R.M., Heinzel F.P., Sadick M.D., Holaday B.J., Gardner K.D. Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets. Ann Inst Pasteur Immunol 1987, 138(September-October (5)):744-749.
29. Tayyari F., Sutton T.C., Manson H.E., Hegele R.G. CpG-oligodeoxynucleotides inhibit RSV-enhanced allergic sensitisation in guinea pigs. Eur Respir J 2005, 25(February (2)):295-302.
30. Radbruch A., Muehlinghaus G., Luger E.O., Inamine A., Smith K.G., Dorner T., et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006, 6(October (10)):741-750.
31. Bemark M., Bergqvist P., Stensson A., Holmberg A., Mattsson J., Lycke N.Y. A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development. J Immunol 2011, 186(February (3)):1399-1410.
32. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H.I., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470(February (7335)):543-547.
33. Schlesinger Y., Granoff D.M. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 1992, 267(March (11)):1489-1494.
34. Lucas A.H., Granoff D.M. Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugates. J Immunol 1995, 154(April (8)):4195-4202.
35. Granoff D.M., Shackelford P.G., Holmes S.J., Lucas A.H. Variable region expression in the antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-protein conjugates. Description of a new lambda light chain-associated idiotype and the relation between idiotype expression, avidity, and vaccine formulation. The Collaborative Vaccine Study Group. J Clin Investig 1993, 91(March (3)):788-796.
36. Nikolai Petrovsky S.H., Honda Y., Bruce Lyons A. New-age vaccine adjuvants: friend or foe?. BioPharm Int 2007, 20(August (8)):A24-A33.
37. Smith J., Lipsitch M., Almond J.W. Vaccine production, distribution, access, and uptake. Lancet 2011, 378(July (9789)):428-438.
38. Bertoletti A., Gehring A. Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Rev Gastroenterol Hepatol 2009, 3(October (5)):561-569.
39. Heath W.R., Carbone F.R. Cytotoxic T lymphocyte activation by cross-priming. Curr Opin Immunol 1999, 11(June (3)):314-318.
40. Hem S.L., Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007, 6(October (5)):685-698.